You searched for
Tag:
Sustainability
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23/06/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07/03/2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24/02/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02/05/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18/10/2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
06/09/2021